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Abstract: Current theory suggests that neurocognitive late effects of treatments for childhood 
cancer such as difﬁ  culties with attention, processing speed and visual-motor ability are the result 
of white matter damage. Neuroimaging studies have produced a variety of white matter ﬁ  ndings. 
However, although white matter is thought to be differentially affected, previous studies have not 
demonstrated a discrepancy between white and gray matter function. The present study included 
36 children treated for childhood leukemia with hematopoietic stem cell transplant (HCT). Their 
performance on neurocognitive measures traditionally thought to measure white matter was 
compared to performance on measures thought to measure gray matter function. Composite 
white and gray matter standard scores were created based on neuropsychological measures that 
individuals with known white or gray matter damage perform poorly. As predicted, composite 
white matter scores (mean = 98.1) were signiﬁ  cantly lower (t = 2.26, p = 0.03) than composite gray 
matter scores (mean = 102.5). Additionally, as gray matter performance increased, the difference 
between gray and white matter scores increased (R = 0.353, p = 0.035). Overall, the results of 
this study support the current theory that white matter damage is responsible for the more subtle 
neurocognitive late effects resulting from treatment for childhood leukemia.
Keywords: late effects of cancer treatment, leukemia, neuropsychology, white matter, brain 
function
Introduction
Childhood leukemia survivors are a population with well-documented neurocognitive 
late effects. Chemotherapy and radiation both are well-documented causes of declines 
in neurocognitive functioning (Waber 2000; Mulhern 2001; Butler and Mulhern 2005; 
Butler and Haser 2006). With continuing advances in therapies, these neurocognitive 
late effects tend to be domain speciﬁ  c and relatively mild, with overall cognitive 
functioning remaining within the average range. With current treatment regimens, 
there is generally no signiﬁ  cant cognitive impairment even in bone marrow transplant 
survivors (Phipps et al 1995; Perkins et al 2007) who have undergone not only the 
initial treatment for their cancer, but the chemotherapy and sometimes radiation given 
as the preparative regimen for transplant. However, speciﬁ  c neurocognitive domains 
like attention, processing speed, and visual-motor precision continue to emerge as 
domains affected (if not impaired) by chemotherapy alone (Waber et al 2000; Butler 
and Haser 2006) as well as radiation (Mulhern 2001; Butler and Haser 2006) in leu-
kemia survivors. Patients who have survived bone marrow transplant as treatment 
for childhood leukemia are at particular risk for neurocognitive late effects, given 
the cumulative effects on the central nervous system of the chemotherapy and often 
radiation treatments they have undergone (Leiper 2002).Neuropsychiatric Disease and Treatment 2008:4(1) 284
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The most widely accepted current theory for the known 
neurocognitive effects of cancer treatment is damage to the 
white matter in the brain (Butler and Haser 2006; Reddick 
et al 2006). The goal of this study is to examine this current 
theory by comparing performance on tests traditionally 
thought to measure white versus gray matter function in a 
population of children treated for childhood leukemia with 
hematopoietic stem cell transplant. Patients are expected to 
perform worse on tests of white matter function than on tests 
of gray matter function.
Theoretical models for neurocognitive 
changes
Axons conveying information from one neuron to the next 
within the brain are insulated by myelin, which is what 
gives white matter its white appearance. Functionally, the 
connectivity between different brain regions is thought to be 
evident in neuropsychological measures such as processing 
speed and visual-spatial or visual-motor tasks that depend on 
communication between multiple regions of the brain (Kolb 
and Wishaw 2003). Reddick and colleagues (2006) suggest 
that “the developing brain may be more susceptible to dam-
age because newly synthesized myelin has higher metabolic 
activity and lower stability that make it more vulnerable to the 
toxic effects of therapy.” Mulhern and colleagues (Mulhern 
1999; Reddick 2000; Mulhern 2001; Reddick 2006) dem-
onstrated a correlation between failure to develop or loss of 
normal appearing white matter, cranial radiation therapy, 
and IQ in pediatric brain tumor survivors.
Although cranial radiation therapy has been strongly 
implicated in white matter changes, chemotherapy alone 
is also thought to have similar effects (Butler and Mulhern 
2005; Moore 2005). A very recent study has linked white 
matter volume with neurocognitive impairments in child-
hood ALL (Reddick et al 2006). Another recent study has 
linked fractional anisotropy in white matter to IQ in child-
hood cancer survivors (Khong et al 2006) Other diseases also 
support this model. For example, children with childhood-
onset cerebral adrenoleukodystrophy, an X-linked disorder 
of the peroxisomes that is characterized by elevations in 
very-long-chain fatty acids, have signiﬁ  cant white matter 
disease. The extent of white matter disease correlates with 
their performance on visual-perceptual tasks including 
Performance IQ and Judgment of Line Orientation and on 
sustained attention measures (Shapiro 2000). White mat-
ter lesions in an elderly population were associated with 
slower psychomotor speed (de Groot and Hofman 2000). 
And white matter disease is also thought to be responsible 
for subtle deﬁ  cits in psychomotor efﬁ  ciency in diabetes 
(Ryan 2003).
It is difﬁ  cult to separate gray and white matter tests, as 
few tasks can truly be localized to one area of the brain. 
However, gray matter function can be assessed through more 
language-based reasoning and memory measures. Language 
is generally considered a cortical function, usually in the left 
hemisphere, and the deep gray matter of the hippocampus 
is also known to be involved in verbal memory (Lezak 
1995). Temporal lobe epilepsy research has demonstrated 
an association between deﬁ  cits in these functions in patients 
with known cortical abnormalities (Bennett and Ho 1989). 
And patients with known white matter lesions were found 
to be unaffected on verbal list-learning tasks (de Groot and 
Hofman 2000).
Neuroradiologic ﬁ  ndings
Evidence of small hemorrhages in the white matter have been 
found in a greater proportion of leukemia survivors, which 
has been attributed to neurotoxicity of methotrexate (Paako 
et al 2003) and to radiation (Chan et al 2006). Wilson and 
colleagues (1991) showed structural white matter changes 
on MRI during chemotherapy for ALL, but the changes were 
no longer evident at three year follow-up. Neuroimaging 
techniques have advanced in recent years from basic struc-
tural MRI to more sophisticated and sensitive techniques 
such as volumetrics, diffusion tensor imaging, and magnetic 
resonance spectroscopy. Gathering evidence from these more 
advanced techniques suggests that in addition to the previ-
ously identiﬁ  ed hemorrhagic lesions, there is diffuse lasting 
white matter damage that is likely attributable to swelling 
(Haykin et al 2006). Preliminary diffusion tensor imaging 
studies have demonstrated decreased white matter diffu-
sion anisotropy after chemotherapy and cranial radiation for 
childhood medulloblastoma and leukemia, which also cor-
related with IQ (Leung 2004; Khong et al 2006). Magnetic 
resonance spectroscopy studies have shown a reduction in 
N-acetyl-aspartate ratios in white matter of leukemia survi-
vors (Chan et al 2001; Chu et al 2003).
Despite the evidence supporting the theory that white 
matter is differentially affected and is responsible for neu-
rocognitive changes following cancer treatment, it remains 
a relatively untested hypothesis. No research has speciﬁ  cally 
compared gray and white matter structure or function in 
childhood leukemia and/or bone marrow transplant survi-
vors in conjunction with neurocognitive functioning. As 
survivorship increases, the importance of understanding how 
cancer treatment affects a child’s brain and its functioning is Neuropsychiatric Disease and Treatment 2008:4(1) 285
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greater than ever before. Studies that provide a link between 
the physiological effects on the brain of cancer treatments 
and functional neurocognitive outcomes that can affect 
quality of life can potentially inform treatment decisions at 
several levels. They can help pediatric oncologists choose 
the safest and most effective treatment for children, moni-
tor treatment effects, and help inform the educational plan 
for children as their cognitive strengths and weaknesses 
and the reasons for these are better understood. In addition, 
through this kind of research, it may eventually be possible 
to use new, non-invasive neuroimaging techniques such as 
diffusion tensor imaging for early identiﬁ  cation of subtle 




Eligible subjects were identiﬁ  ed from the University of Min-
nesota HCT database with a history of ALL or AML, who had 
survived  1 year after HCT, and were currently in remission. 
Eligible patients were initially mailed a letter describing the 
study. In those cases without response, an attempt was made 
to contact patients by telephone. Data was available from a 
total of 36 patients on all necessary measures.
Participants ranged from 8 to 18 years of at testing. They 
were transplanted between 6 months-old and 12 years-old 
(mean of 6 years-old) between 1981 and 2000. One patient 
received two transplants. They were anywhere from 1 year 
to 14 ½ years from time of transplant at testing (mean 
of 7 years). Thirty-two patients had received total body 
irradiation while 4 had not. All received chemotherapy on a 
variety of different protocols. Children with a diagnosis of 
Down syndrome were not included in this study.
Data collection
The HCT database of the University of Minnesota Blood 
and Marrow Transplantation Program was utilized for 
obtaining relevant transplant related data speciﬁ  c transplant 
related outcomes. After obtaining informed consent, sur-
vivors (accompanied by a parent) were scheduled through 
the General Clinical Research Center at the University of 
Minnesota. A description of the complete research protocol 
can be found in Perkins and colleagues (2007) Long-term 
Follow-up of Children who Underwent Hematopoeitic Cell 
Transplant (HCT) for AML or ALL at Less than Three 
Years of Age: The University of Minnesota Experience. All 
participants underwent the same set of neuropsychological 
tests, administered by a psychometrist who was blinded 
to the patients’ treatment history. Scoring and analysis 
of these tests is also standardized and was performed by 
the same individual. All components of this testing were 
standardized, age-speciﬁ  c and are utilized in routine clini-
cal neuropsychological practice. Testing was completed in 
the neuropsychology clinic at The University of Minnesota 
Hospital and in the GCRC.
Composite variables
Composite variables were formed using a disease model 
by averaging standard scores across speciﬁ  c measures on 
which people with known white or gray matter involvement 
do poorly. All scores were transformed to standard scores. 
Verbal reasoning and memory are thought to reﬂ  ect gray 
matter functions, while attention, processing speed, and 
visual-spatial and visual-motor coordination are thought to 
reﬂ  ect white motor functioning. A gray matter composite 
was calculated as a mean of the total score for trials 1–5 on 
the California Verbal Learning Test – Children’s version 
(CVLT-C) and the Verbal Intellectual Quotient (VIQ) on 
the Wechsler Abbreviated Scale of Intelligence (WASI). The 
white matter composite score was calculated as an average of 
a Conners’ Continuous Performance Test (CPT) composite 
(an average of the omissions, response time and variability 
scores, created so as to not weight one test more heavily than 
the other) and the Block Design score from the WASI.
Analyses
Descriptive statistics were run on the variables making up 
the composite gray and white matter scores, and also on the 
gray and white matter composite variables. A paired sample, 
two-tailed t-test was run to test for differences between per-
formance on gray versus white matter tests. Finally a Pearson 
correlation coefﬁ  cient was computed for overall gray matter 
score and the difference between scores on gray and white 
matter measures.
Results
Overall, results of descriptive statistics are consistent with 
previous literature in ﬁ  nding that intellectual ability remained 
comparable to the normative population (mean = 100, stan-
dard deviation = 15). Verbal IQ was slightly higher than 
Performance IQ, but not signiﬁ  cantly so, and the standard 
deviation of these scores was not signiﬁ  cantly different from 
normal. CPT scores also fell within the average range, but 
had a wide range. Subjects also scored similar to the aver-
age population on the CVLT-C. Table 1 summarizes these 
descriptive statistics.Neuropsychiatric Disease and Treatment 2008:4(1) 286
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The means and standard deviations of the white and gray 
matter composite scores also fell within the average range 
(Table 2). Although within the average range, however, 
there was a signiﬁ  cant difference between gray and white 
matter function (t = 2.26, p = 0.03), with subjects scoring 
lower on the white matter composite than on the gray matter 
composite (Table 3).
Upon completion of testing, it was apparent from qualita-
tive review of the data that while there were quite a few patients 
who performed well above average on most tasks, there were 
also several who were globally impaired. It seemed that some 
patients were globally impaired, reﬂ  ecting damage to their 
whole brains, while patients with only subtle difﬁ  culties evi-
denced those difﬁ  culties on the white matter tests. To address 
this question, a Pearson correlation coefﬁ  cient was calculated 
for the difference between scores on gray and white matter 
measures and gray matter performance. As gray matter perfor-
mance increased, the difference between gray and white matter 
scores increased (R = 0.353, p = 0.035). That is, subjects who 
performed poorly on gray matter tests, performed similarly 
badly on white matter tests. However, patients who scored 
closer to average or above average had a greater discrepancy 
between their gray and white matter test scores.
Discussion
Overall, the results of this study support previous research 
documenting only minimal neurocognitive sequelae for most 
transplant survivors, but greater effects on tasks thought to 
reﬂ  ect white matter function than on tasks thought to measure 
gray matter function. That is, the chemotherapy and radia-
tion associated with stem cell transplant and general treat-
ment for childhood leukemia appears to differentially affect 
white matter over gray matter in the brain. Additionally, the 
discrepancy between performance on gray versus white mat-
ter tasks increased as overall level of functioning increased. 
Although some patients experience CNS toxicity that leads 
to general cognitive compromise, those with only subtle 
difﬁ  culties evidence those difﬁ  culties differentially on white 
matter tests.
These ﬁ  ndings lend support to the current hypothesis that 
white matter damage is responsible for most neurocognitive 
late effects. Previous studies have shown transient hyperin-
tensities in white matter. Reddick and colleagues (Reddick 
2006) suggested that these transient hyperintensities observed 
on MRI may lead to permanent subtle white matter damage, 
as seen in the persistent white matter volume changes and 
associated functional declines following treatment for child-
hood leukemia.
The question becomes how and when we can best identify 
these subtle white matter changes. As therapies continue to 
improve, quality of life and even minor declines in function-
ing become increasingly important. Identifying even the most 
subtle effects of different chemotherapies will be helpful to 
both patients and researchers. The earlier the identiﬁ  cation 
of even subtle brain damage, the easier it will be for patients 
to develop compensatory strategies and effectively reinte-
grate into the classroom. Also, the ability to identify subtle 
changes as early as possible will also help researchers as 
they develop increasingly effective therapies with fewer and 
fewer side effects. Newer neuroimaging techniques such as 
diffusion tensor imaging (DTI) paired with domain-speciﬁ  c 
neurocognitive testing may help in the early identiﬁ  cation 
of this subtle white matter damage.
The current study had several limitations. First, without 
baseline data or a matched control sample, it was impossible 
to determine how subjects’ performance compared with their 
functioning prior to their illness or with similar individuals 
without leukemia or its treatments. Additionally, this was 
a very heterogeneous population, including diagnoses of 
AML and ALL, with differing treatments (including many 
Table 1 Descriptive statistics
 Minimum  Maximum  Mean  Standard  deviation
WASI Full scale IQ  74  127  101.53  14.68
WASI Verbal IQ  71  140  100.90  14.46
CPT Omissions standard score  40  179  105.34  24.57
WASI Block design  67  127  97.50  17.99
CPT Response time standard score  28  151  93.88  24.03
CPT Variability standard score  40  136  97.54  22.34
CVLT Trials 1–5 standard score  76  124  103.33  11.59
Abbreviations: CPT, Conner’s Continuous Performance Test; CVLT, California Verbal Learning Test; WASI, Wechsler Abbreviated Scale of Intelligence.
Table 2 Paired samples statistics
 Mean  Standard  deviation
White 98.07  13.06
Gray 102.53  11.28Neuropsychiatric Disease and Treatment 2008:4(1) 287
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with radiation, a few without). Time since diagnosis and 
treatment was variable, as was age at diagnosis and treat-
ment. These are all variables known to play a role in the 
emergence of neurocognitive late effects. Additionally, 
although the composite variables were developed based on 
prior studies showing that known lesions in white or gray 
matter differentially affect performance on those tests, this 
is a less than perfect method. Real world functional tasks 
generally activate a number of regions or circuits within the 
brain (Page 2006), and research has not combined functional 
magnetic resonance imaging with functional activities to 
develop speciﬁ  c gray or white matter tasks.
However, the fact that results reached statistical signiﬁ  -
cance even with these limitations suggests that the white matter 
theory is robust, and worthy of further exploration. Future 
studies should utilize the most sensitive neuroimaging and neu-
ropsychological techniques available to reﬁ  ne our understand-
ing of how white matter is affected, and help us to determine 
how best to improve quality of life and functioning of the ever 
increasing population of childhood cancer survivors.
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